JP2007516232A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516232A5
JP2007516232A5 JP2006533319A JP2006533319A JP2007516232A5 JP 2007516232 A5 JP2007516232 A5 JP 2007516232A5 JP 2006533319 A JP2006533319 A JP 2006533319A JP 2006533319 A JP2006533319 A JP 2006533319A JP 2007516232 A5 JP2007516232 A5 JP 2007516232A5
Authority
JP
Japan
Prior art keywords
antibody
glial
type
tumor antigen
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006533319A
Other languages
English (en)
Japanese (ja)
Other versions
JP4703567B2 (ja
JP2007516232A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/016121 external-priority patent/WO2004112829A2/en
Publication of JP2007516232A publication Critical patent/JP2007516232A/ja
Publication of JP2007516232A5 publication Critical patent/JP2007516232A5/ja
Application granted granted Critical
Publication of JP4703567B2 publication Critical patent/JP4703567B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006533319A 2003-05-23 2004-05-21 膠細胞起源の腫瘍の診断と治療のための組成物と方法 Expired - Fee Related JP4703567B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47323803P 2003-05-23 2003-05-23
US60/473,238 2003-05-23
US54829904P 2004-02-27 2004-02-27
US60/548,299 2004-02-27
PCT/US2004/016121 WO2004112829A2 (en) 2003-05-23 2004-05-21 Compositions and methods for the diagnosis and treatment of tumors of glial origin

Publications (3)

Publication Number Publication Date
JP2007516232A JP2007516232A (ja) 2007-06-21
JP2007516232A5 true JP2007516232A5 (enExample) 2007-08-02
JP4703567B2 JP4703567B2 (ja) 2011-06-15

Family

ID=33544287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533319A Expired - Fee Related JP4703567B2 (ja) 2003-05-23 2004-05-21 膠細胞起源の腫瘍の診断と治療のための組成物と方法

Country Status (9)

Country Link
US (2) US20050112129A1 (enExample)
EP (1) EP1628679A2 (enExample)
JP (1) JP4703567B2 (enExample)
KR (1) KR20060015296A (enExample)
AU (1) AU2004249125A1 (enExample)
CA (1) CA2524567A1 (enExample)
MX (1) MXPA05012613A (enExample)
NZ (1) NZ543751A (enExample)
WO (1) WO2004112829A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
KR100623128B1 (ko) * 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
KR20060013425A (ko) * 2003-05-29 2006-02-09 밀레니엄 파머슈티컬스 인코퍼레이티드 유방암의 확인, 평가, 예방 및 요법에 대한 조성물, 키트및 방법
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7824685B2 (en) * 2004-01-26 2010-11-02 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer
JP4840866B2 (ja) * 2005-01-19 2011-12-21 学校法人慶應義塾 癌ワクチン
DE602006020576D1 (de) * 2005-07-26 2011-04-21 Council Scient Ind Res Verfahren zur gliomdiagnose mit unterscheidung zwischen progressiven und de-novo-formen
ES2330904B1 (es) * 2005-09-21 2010-09-23 Fundacio Centre De Recerca En Sanitat Animal Polinucleotidos de haemophilus parasuis y su uso.
US7482131B2 (en) * 2005-11-15 2009-01-27 United States Department Of Veterans Affairs Detection of PKC-iota as a biomarker for brain tumorigenesis
EP1993596B1 (en) 2006-03-13 2012-08-15 Novovacs Holding B.V. Cancer vaccine
CL2007003422A1 (es) * 2006-11-29 2008-06-20 Genentech Inc Uso de un antagonista de la proteina pik3r3 para inhibir el crecimiento de un glioma que expresa dicha proteina; y metodo para diagnosticar la presencia de un glioma en un mamifero.
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
EP2185198B1 (en) 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox and l0xl2 inhibitors and uses thereof
KR20100053607A (ko) 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 항-ｔｗｅａｋ 수용체 항체의 치료 용도
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
CN102232113A (zh) * 2008-03-31 2011-11-02 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2216399A1 (en) * 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
KR20120063488A (ko) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. 리실 옥시다제 및 ｌｏｘｌ２로부터의 촉매 도메인
JP2013502228A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． ｉｎｖｉｔｒｏスクリーニングアッセイ
RU2015108348A (ru) 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2013533732A (ja) * 2010-05-03 2013-08-29 ジェネンテック， インコーポレイテッド 腫瘍の診断と治療のための組成物と方法
CA2816021A1 (en) * 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3012006A1 (en) * 2017-07-31 2019-01-31 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
CN120569400A (zh) * 2022-11-14 2025-08-29 德克萨斯大学系统董事会 使用硝化抗性ccl2趋化因子的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6150162A (en) 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
MXPA01010891A (es) * 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
MXPA04002593A (es) * 2001-09-18 2004-05-31 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumor.

Similar Documents

Publication Publication Date Title
JP2007516232A5 (enExample)
US20110020221A1 (en) Cancer stem cell expression patterns and compounds to target cancer stem cells
Marangoni et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
JP2008546780A5 (enExample)
HRP20170743T1 (hr) Anti-ceacam5 protutijela i njihova uporaba
JP2010537671A5 (enExample)
JP2013520174A5 (enExample)
JP2010510809A5 (enExample)
WO2015066279A2 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
JP2007504280A5 (enExample)
CA2633171A1 (en) Antibodies against tumor-associated antigenic target (tat) polypeptides
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
Hicks et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
JP2009536834A5 (enExample)
JP2011502517A5 (enExample)
AR050642A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
JP2010518847A5 (enExample)
Li et al. Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer
JP2015533788A5 (enExample)
JP2015523852A5 (enExample)
CA2611778A1 (en) Compositions and methods for the diagnosis and treatment of tumor
RU2012127351A (ru) Композиции и способы для диагностики и лечения опухоли
RU2012140451A (ru) Композиции и способы для диагностики и лечения опухолей
JP2014515600A5 (enExample)
Duanmu et al. Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy